Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study

To evaluate the relation between T2 lesions and disease severity in relapsing‐remitting multiple sclerosis (MS).

[1]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[2]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.

[3]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[4]  O. Andersen,et al.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.

[5]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[6]  W. I. McDonald,et al.  Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.

[7]  R. Grossman,et al.  Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. , 1995, AJNR. American journal of neuroradiology.

[8]  B. Weinstock-Guttman,et al.  A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients , 1995 .

[9]  A J Thompson,et al.  Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.

[10]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[11]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[12]  M Filippi,et al.  Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis , 1996, Acta neurologica Scandinavica.

[13]  Christian Confavreux,et al.  Recommendations from the national multiple sclerosis society clinical outcomes assessment task force , 1997, Annals of neurology.

[14]  Jeanelle Sheeder,et al.  Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .

[15]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[16]  J H Simon,et al.  Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. , 1998, Annals of neurology.

[17]  A J Thompson,et al.  Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. , 1999, Neurology.

[18]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[19]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[20]  J K Udupa,et al.  Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.

[21]  D. Li,et al.  Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. , 1999, Annals of neurology.

[22]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[23]  G Cutter,et al.  Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS , 2001, Neurology.

[24]  R. Zivadinov,et al.  Is Gadolinium Enhancement Predictive of the Development of Brain Atrophy in Multiple Sclerosis? A Review of the Literature , 2002, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[25]  Maria Liguori,et al.  Age‐related disability in multiple sclerosis , 2002, Annals of neurology.

[26]  F. Barkhof.  The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[27]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[28]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[29]  C. Pozzilli,et al.  The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis , 2004, Journal of Neurology.

[30]  Norbert Schuff,et al.  Comparisons between Global and Focal Brain Atrophy Rates in Normal Aging and Alzheimer Disease: Boundary Shift Integral versus Tracing of the Entorhinal Cortex and Hippocampus , 2004, Alzheimer disease and associated disorders.

[31]  R. Rudick,et al.  Defining interferon beta response status in multiple sclerosis patients. , 2004, Annals of neurology.

[32]  S. Ropele,et al.  Risk factors for progression of brain atrophy in aging Six-year follow-up of normal subjects , 2022 .